How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

Development of ABS-101: A potential best-in-class anti-TL1A antibody for the treatment of IBD

calendar_today November 12, 2024 person Jarred Yacob domain absci

The post Development of ABS-101: A potential best-in-class anti-TL1A antibody for the treatment of IBD appeared first on Absci .

open_in_new Read original post